{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:51:32Z","timestamp":1791384692913,"version":"4.3.3"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100016912","name":"MSD France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We evaluated the efficacy and safety of a once-daily oral two-drug regimen (2DR) combining doravirine and raltegravir in virologically suppressed people with HIV (PWH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>DORAL is a multicentre, open-label, randomized phase II trial conducted in France, Italy, and Spain. Virologically suppressed adults receiving stable antiretroviral therapy (ART), na\u00efve to doravirine and without raltegravir resistance, were randomized (2:1) either to switch immediately to doravirine (100\u2005mg) plus raltegravir (1200\u2005mg) or to continue baseline ART until week 48 before switching to doravirine plus raltegravir. The primary endpoint was virological failure (VF; confirmed plasma HIV-1-RNA \u226550\u2005copies\/mL) at week 48. Secondary endpoints included maintenance of virological suppression through W96, immunological outcomes, safety, and pharmacokinetics in a genital sub-study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 114 participants (median age, 57\u2005years; median CD4 count, 700\u2005cells\/mm3; median duration of virological suppression, 10\u2005years), one VF occurred by week 48 in the immediate-switch group (1.3%; 95% CI, 0.0\u20136.9); none occurred in the delayed-switch group. No additional VF was observed through week 96. Immunological parameters remained stable during follow-up. Three adverse events considered related to doravirine and raltegravir led to treatment discontinuation. One grade 3 adverse event (anxiety), considered related to study treatment, was reported. In the genital sub-study, drug concentrations exceeded inhibitory thresholds in most samples, with infrequent detection of low-level seminal HIV-1-RNA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This proof-of-concept phase II switch trial supports the feasibility of a once-daily doravirine plus raltegravir 2DR in selected PWH, particularly when minimizing drug-drug interactions or avoiding NRTI exposure is a priority.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag336","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:09:44Z","timestamp":1790334584000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of switching to once-daily oral doravirine plus raltegravir in virologically suppressed people with HIV-1: a randomized, open-label, multicentre phase 2 study (DORAL)"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0047-0101","authenticated-orcid":false,"given":"Romain","family":"Palich","sequence":"first","affiliation":[{"name":"Paris Cit\u00e9 University, INSERM, Centre for Research in Epidemiology and Statistics (CRESS), AP-HP, H\u00f4tel-Dieu Hospital, Immunology and Infectious Diseases Department , 1 place du Parvis Notre-Dame, Paris 75013 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-8288","authenticated-orcid":false,"given":"Minh P","family":"L\u00ea","sequence":"additional","affiliation":[{"name":"Paris Cit\u00e9 University, INSERM, IAME UMR1137, AP-HP, Bichat-Claude Bernard Hospital, Toxicology and Pharmacology Department , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University, San Raffaele Scientific Institute , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-1270","authenticated-orcid":false,"given":"Clotilde","family":"Allavena","sequence":"additional","affiliation":[{"name":"Nantes University Hospital, Infectious Diseases Department , Nantes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2121-4684","authenticated-orcid":false,"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[{"name":"National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS , Roma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Canetti","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University, San Raffaele Scientific Institute , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-873X","authenticated-orcid":false,"given":"Juan","family":"Tiraboschi","sequence":"additional","affiliation":[{"name":"University of Barcelona, Bellvitge University Hospital, IDIBELL, Barcelona, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5696-4173","authenticated-orcid":false,"given":"Claudine","family":"Duvivier","sequence":"additional","affiliation":[{"name":"Paris Cit\u00e9 University, IHU Imagine, AP-HP, Necker Hospital, Necker-Pasteur Infectiology Center, Infectious Diseases Department , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-8846","authenticated-orcid":false,"given":"Esteban","family":"Martinez","sequence":"additional","affiliation":[{"name":"University of Barcelona, Spain Hospital Cl\u00ednic Barcelona, Instituto de Investigaciones Biom\u00e9dicas August Pi i Sunyer (IDIBAPS), Reial Acad\u00e8mia de Medicina de Catalunya (RAMC) , Barcelona , , , Madrid ,","place":["Spain Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Barcelona , , , Madrid ,","place":["Spain Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1138-5770","authenticated-orcid":false,"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau, HIV Unit, Infectious Diseases Department , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salima","family":"Barkat","sequence":"additional","affiliation":[{"name":"Sorbonne University, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP) , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Dudoit","sequence":"additional","affiliation":[{"name":"Sorbonne University, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Infectious Diseases Department , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydie","family":"B\u00e9niguel","sequence":"additional","affiliation":[{"name":"Sorbonne University, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP) , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-537X","authenticated-orcid":false,"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"Paris Cit\u00e9 University, INSERM, IAME UMR1137, AP-HP, Bichat-Claude Bernard Hospital, Toxicology and Pharmacology Department , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Sorbonne University, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Virology Department , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2032-4148","authenticated-orcid":false,"given":"Cathia","family":"Souli\u00e9","sequence":"additional","affiliation":[{"name":"Sorbonne University, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Virology Department , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert","family":"Assoumou","sequence":"additional","affiliation":[{"name":"Sorbonne University, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP) , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[{"name":"Sorbonne University, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Infectious Diseases Department , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the DORAL Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziza","family":"Chermak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Dudoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na\u00efma","family":"Hamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Ktorza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Palich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoual","family":"Qatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luminata","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Tubiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Antoine","family":"Valantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Duvivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabete","family":"Gomes Pires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Louisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert","family":"Assoumou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Averlant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salima","family":"Barkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydie","family":"Beniguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abir","family":"Boulegroune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassima","family":"Boumghar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stahlberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Tobbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Vilmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Allavena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morane","family":"Cavallec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Paredes Manyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Raffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albane","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Aliverti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Annicchiarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Canetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Gagliardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Maddalena","family":"Plazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Chivite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Tiraboschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"2026100709585458000_dkag336-B1","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/QAD.0000000000001476","article-title":"Individualized antiretroviral therapeutic approaches: less can be more","volume":"31","author":"Katlama","year":"2017","journal-title":"AIDS Lond Engl"},{"key":"2026100709585458000_dkag336-B2","doi-asserted-by":"publisher","first-page":"e868","DOI":"10.1016\/S2352-3018(22)00249-1","article-title":"Two-drug regimens for HIV treatment","volume":"9","author":"Gibas","year":"2022","journal-title":"Lancet HIV"},{"key":"2026100709585458000_dkag336-B3","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose two-drug regimen versus continuing a tenofovir alafenamide-based three- or four-drug regimen for maintenance of virologic suppression in adults with HIV-1: phase 3, randomized, non-inferiority TANGO study","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026100709585458000_dkag336-B4","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026100709585458000_dkag336-B5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"2026100709585458000_dkag336-B6","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1093\/jac\/dkz224","article-title":"Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the phase II ANRS 163 ETRAL study","volume":"74","author":"Katlama","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026100709585458000_dkag336-B7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/jac\/dkaa423","article-title":"Once-daily etravirine\/raltegravir (400\/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine\/raltegravir (200\/400 mg q12 h) regimen","volume":"76","author":"Palich","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026100709585458000_dkag336-B8","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"2026100709585458000_dkag336-B9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"2026100709585458000_dkag336-B10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/cid\/cir510","article-title":"Long-term treatment with raltegravir or efavirenz combined with tenofovir\/emtricitabine for treatment-naive human immunodeficiency virus-1\u2013infected patients: 156-week results from STARTMRK","volume":"53","author":"Rockstroh","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2026100709585458000_dkag336-B11","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"2026100709585458000_dkag336-B12","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","article-title":"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials","volume":"375","author":"Eron","year":"2010","journal-title":"Lancet"},{"key":"2026100709585458000_dkag336-B13","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1097\/QAD.0b013e32833a608a","article-title":"Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study","volume":"24","author":"Mart\u00ednez","year":"2010","journal-title":"AIDS"},{"key":"2026100709585458000_dkag336-B14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/157016211794582650","article-title":"Long-term safety from the raltegravir clinical development program","volume":"9","author":"Teppler","year":"2011","journal-title":"Curr HIV Res"},{"key":"2026100709585458000_dkag336-B15","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/S2352-3018(19)30336-4","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial","volume":"7","author":"Molina","year":"2020","journal-title":"Lancet HIV"},{"key":"2026100709585458000_dkag336-B16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/cid\/ciy540","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial","volume":"68","author":"Orkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026100709585458000_dkag336-B17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/QAI.0000000000002056","article-title":"Switching to doravirine\/lamivudine\/tenofovir disoproxil fumarate (DOR\/3TC\/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial","volume":"81","author":"Johnson","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026100709585458000_dkag336-B18","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/AAC.04201-14","article-title":"In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways","volume":"59","author":"Feng","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026100709585458000_dkag336-B19","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1016\/S2352-3018(17)30128-5","article-title":"Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial","volume":"4","author":"Cahn","year":"2017","journal-title":"Lancet HIV"},{"key":"2026100709585458000_dkag336-B20","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"2026100709585458000_dkag336-B21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3851\/IMP2920","article-title":"Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects","volume":"20","author":"Anderson","year":"2015","journal-title":"Antivir Ther"},{"key":"2026100709585458000_dkag336-B22","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/QAI.0b013e31802b4956","article-title":"Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals","volume":"43","author":"Markowitz","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026100709585458000_dkag336-B23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/COH.0000000000000608","article-title":"Polypharmacy in HIV: recent insights and future directions","volume":"15","author":"Edelman","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"key":"2026100709585458000_dkag336-B24","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s40261-020-00934-2","article-title":"Clinical pharmacokinetics of the novel HIV-1 non-nucleoside reverse transcriptase inhibitor doravirine: an assessment of the effect of patient characteristics and drug-drug interactions","volume":"40","author":"Khalilieh","year":"2020","journal-title":"Clin Drug Investig"},{"key":"2026100709585458000_dkag336-B25","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s40262-019-00806-9","article-title":"Clinical pharmacodynamics, pharmacokinetics, and drug interaction profile of doravirine","volume":"58","author":"Boyle","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2026100709585458000_dkag336-B26","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/clpt.2009.12","article-title":"Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms","volume":"85","author":"Wenning","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"2026100709585458000_dkag336-B27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029855","article-title":"Real-life use of doravirine in treatment-experienced people living with HIV: a multicenter Italian study","volume":"101","author":"Mazzitelli","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"2026100709585458000_dkag336-B28","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/hiv.13615","article-title":"Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations","volume":"25","author":"Rossotti","year":"2024","journal-title":"HIV Med"},{"key":"2026100709585458000_dkag336-B29","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1093\/jac\/dkad185","article-title":"Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study","volume":"78","author":"Perfezou","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026100709585458000_dkag336-B30","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0140-6736(25)01948-8","article-title":"Switch to fixed-dose doravirine (100 mg) and islatravir (0\u00b725 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial","volume":"407","author":"Colson","year":"2026","journal-title":"Lancet"},{"key":"2026100709585458000_dkag336-B31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0140-6736(25)01945-2","article-title":"Switch to fixed-dose doravirine (100 mg) and islatravir (0\u00b725 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial","volume":"407","author":"Orkin","year":"2026","journal-title":"Lancet"},{"key":"2026100709585458000_dkag336-B32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/jac\/dkaa401","article-title":"In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations","volume":"76","author":"Saladini","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026100709585458000_dkag336-B33","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/QAI.0000000000002496","article-title":"Review of doravirine resistance patterns identified in participants during clinical development","volume":"85","author":"Martin","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026100709585458000_dkag336-B34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12981-023-00503-5","article-title":"Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance","volume":"20","author":"Rhee","year":"2023","journal-title":"AIDS Res Ther"},{"key":"2026100709585458000_dkag336-B35","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11904-024-00708-x","article-title":"Metabolic complications associated with use of integrase strand transfer inhibitors (InSTI) for the treatment of HIV-1 infection: focus on weight changes, lipids, glucose and bone metabolism","volume":"21","author":"Savinelli","year":"2024","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2026100709585458000_dkag336-B36","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/cid\/cit252","article-title":"Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men","volume":"57","author":"Gianella","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2026100709585458000_dkag336-B37","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1093\/cid\/ciu187","article-title":"HIV-1 DNA levels in peripheral blood mononuclear cells and cannabis use are associated with intermittent HIV shedding in semen of men who have sex with men on successful antiretroviral regimens","volume":"58","author":"Ghosn","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026100709585458000_dkag336-B38","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01401-25","article-title":"Contemporary antiretroviral pharmacology in the male genital tract: implications for HIV treatment and prevention","volume":"70","author":"Neverette","year":"2026","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/11\/dkag336\/71665680\/dkag336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/11\/dkag336\/71665680\/dkag336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:58:59Z","timestamp":1791381539000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag336\/8875743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag336","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,10,6]]},"article-number":"dkag336"}}